

Expertise. Innovation. Reliability.

When your needs call for a contract services organization, Avecia OligoMedicines stands ready. Whether it's in the development, manufacturing or analysis of therapeutic oligonucleotides, Avecia is committed to exceeding your expectations.

You can rely on our FDA-inspected facility to manufacture active pharmaceutical ingredients (API) that meet the international requirements of ICH Q7. We have more than 15-years experience synthesizing siRNA, aptamers, chimeras, DNA, RNA and molecular decoys. It's no wonder we are the manufacturing partner for more than 1,000 different sequences at production scale.

Whether you are in preclinical stages, or ready for a commercial launch, you can be assured of the best in both technology and service when you turn to the world-leading capabilities of Avecia.

Benefit from all our **experience**, starting with your first gram.



Current operational equipment includes:

Synthesis

- 5 x 1-6mmol Akta OligoPilot™100
- 1 x 3-30mmol OligoPilot™400
- 1 x 100-300mmol OligoProcess™
- 3 x 300-600mmol OligoProcess™

Purification

- 4 x 1-10mmol (Akta Explorer™; Gilson)
- 1 x 20-100mmol unit
- 3 x 100-300mmol BioProcess™

Ultra-Filtration

- 1 x 10mmol Sartorius Alpha UF
- 2 x 1200mmol CUF TFF system
- 1 x 1200mmol SciLog System
- 4 flexible scale TFF systems

Freeze drying

- Multiple small scale (1-10mmol) units
- 1 x 250g unit
- 1 x 500g unit
- 2 x 3600g unit (KTS/BOC)

Our services include:

- API production from your first gram to hundreds of kilograms
- Oligonucleotide characterization
- Analytical method development from proof of concept through validation
- Stability studies for drug substance and drug product
- Process development via rigorous, statistical, Quality by Design (QBD) based approach
- CMC, IND and IMPD technical support
- Intimate control of supply chain to ensure quality, reproducibility and safety